Compare · INMD vs OM
INMD vs OM
Side-by-side comparison of InMode Ltd. (INMD) and Outset Medical Inc. (OM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and OM operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $912.4M, about 11.0x OM ($82.8M).
- Over the past year, INMD is up 1.0% and OM is down 61.1% - INMD leads by 62.1 points.
- OM has been more active in the news (6 items in the past 4 weeks vs 1 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 13 for OM).
- Company
- InMode Ltd.
- Outset Medical Inc.
- Price
- $14.40+0.14%
- $4.53-0.88%
- Market cap
- $912.4M
- $82.8M
- 1M return
- +4.80%
- +28.37%
- 1Y return
- +1.02%
- -61.13%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- 2020
- News (4w)
- 1
- 6
- Recent ratings
- 20
- 13
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Outset Medical Inc.
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It offers Tablo Hemodialysis System, which comprises of a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
Latest INMD
- InMode to Report First Quarter 2026 Financial Results and Hold Conference Call on May 6, 2026, Expects Q1 Revenue Between $81.5M-$81.7M, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- InMode to Present at the 25th Annual Needham Virtual Healthcare Conference
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by new insider Mizrahy Moshe
- SEC Form 3 filed by new insider Kreindel Michael
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 3 filed by InMode Ltd.
- SEC Form 6-K filed by InMode Ltd.
Latest OM
- SEC Form DEFA14A filed by Outset Medical Inc.
- SEC Form DEF 14A filed by Outset Medical Inc.
- SEC Form 4 filed by Elliott Derick A.
- SEC Form 3 filed by new insider Elliott Derick A.
- Outset Medical Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Outset Medical Names Derick Elliott as Executive Vice President of Commercial
- Amendment: SEC Form SCHEDULE 13G/A filed by Outset Medical Inc.
- Amendment: New insider Leonard Braden Michael claimed ownership of 1,902,201 shares (SEC Form 3)
- General Counsel Brottem John L. sold $9,521 worth of shares (2,842 units at $3.35), decreasing direct ownership by 8% to 32,935 units (SEC Form 4)
- Chair and CEO Trigg Leslie sold $11,259 worth of shares (3,361 units at $3.35), decreasing direct ownership by 3% to 102,342 units (SEC Form 4)